SOUTH SAN FRANCISCO, Calif. & LONDON--(BUSINESS WIRE)--Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation ...

Cellares has raised a $257 million Series D financing, bringing its total funding to $612 million. The latest comes as the cell therapy manufacturing company accelerates plans to industrialize ...

CytoNiche’s 3D FloTrix™ platform won the Emerging Bioprocessing Supplier – Downstream award at ABEA 2026, recognising ...

The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...

As demand for CAR T therapies strain traditional manufacturing, Autolus Therapeutics has tapped Cellares to evaluate whether that company’s automated Cell Shuttle platform can support expanded ...

The "Cell and Gene Therapy Manufacturing Market -- Growth, Share, Opportunities & Competitive Analysis, 2024 -- 2032" report has been added to the Credence Research Inc. offering. The global Cell and ...

Collaboration with Stanford Medicine establishes a platform manufacturing process and analytics designed to support gene-edited hematopoietic stem cell therapies for HIV and more than 19 rare diseases ...

Automation in cell and gene therapy manufacturing promises lower costs, improved efficiency, and expanded access to life-saving treatments worldwide.

Taiwan Bio will leverage the Quantum Flex™ Cell Expansion System 3-in-1 workflow beyond CAR-T to support development of regulatory T-cell therapies Program will evaluate simplified, scalable, ...

Autolus will evaluate Cellares’ fully automated, high-throughput manufacturing platform in preparation for expansion into new indications Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage ...

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced a collaboration with the Stanford Center for Definitive and Curative Medicine (CDCM) and Stanford ...